EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients

International Journal of Cancer

Volumn 122, Issue 3, 2008, Pages 595-602

  Laitinen, Sari ^a   Martikainen, Paula M ^b   Tolonen, Teemu ^b   Isola, Jorma ^a   Tammela, Teuvo L J ^b   Visakorpi, Tapio ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Carcinoma; Immunostaining; Neoplasia; Prostatic; Survival

Indexed keywords

GENE PRODUCT; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROTEIN EZH2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; EIF3S3 GENE; EZH2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MCM7 GENE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADULT; AGED; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349004833     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23145     Document Type: Article

References (42)

1. Isola J, Auvinen A, Poutiainen M, Kakkola L, Jarvinen TA, Maattanen L, Stenman UH, Tammela T, Hakama M, Visakorpi T. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J Urol 2001;165:1569-74.
2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, et al. Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
3. Carver BS, Bianco FJ, Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006;176:564-8.
4. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
5. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, et al. Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-50.
6. Nelson CP, Rubin MA, Strawderman M, Montie JE, Sanda MG. Pre-operative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology 2002;59:740-5.
7. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
8. Sivridis E, Touloupidis S, Giatromanolaki A. Immunopathological prognostic and predictive factors in prostate cancer. Int Urol Nephrol 2002;34:63-71
9. Allsbrook WC, Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 2001;32:81-8.
10. Allsbrook WC, Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:74-80.
11. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87.
12. Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur Urol 2004;45:683-91.
13. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-29.
14. Rhodes DR, Sandra MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-8.
15. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73.
16. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast ephitelial cells. Proc Natl Acad Sci USA 2003;100:11606-11.
17. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N, Abate-Shen C, Farnham P, Reinberg D. Composition and histone subtrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 2005;102:1859-64.
18. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene EZH2 is required for early mouse development. Mol Cell Biol 2001;21:4330-6.
19. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
20. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-69.
21. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zsete homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24:6269-80.
22. Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enchancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006;45:639-45.
23. Maiorano D, Lamaitre JM, Mechali M. Stepwise regulated chromatin assembly of MCM 2-7 proteins. J Biol Chem 2000;12:8426-31.
24. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, Weinberg V, Carroll PR, Tlsty TD. Minichromosome maintenance protein 2 expression in prostate: characterization and association in outcome after therapy for cancer. Clin Cancer Res 2001;7:2712-18.
25. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein MCM7 as a marker of proliferation in prostate cancer. J Clin Pathol 2004;57:1057-62.
26. Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J, Michalopoulos G, Yu YP, Luo JH. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006;25:1090-8
27. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
28. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
29. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WC, van Der Kwast TT, Schroder FH, Tanke HJ, van Dekken H. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 2001;158:399-406.
30. Ribeiro FR, Jeronimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12:3961-70.
31. Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 1999;154:1777-83.
32. Saramaki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 2001;159:2089-94.
33. Sobin LH, Wittekind C, eds. International union against cancer: TNM classification of malignant tumours, 5th ed. New York: Wiley, 1997.170-3.
34. Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi O-P, Isola J. Improved technique for analysis of formalin-fixed paraffin embedded tumors by fluorescence in situ hybridization. Cytometry 1994;16:93-9.
35. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation follow ing radical prostatectomy. JAMA 1999;281:1642-5.
36. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D;Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9.
37. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment verus observation after radical prostatectomy for locally advanced lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
38. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, et al. Docetaxel and estramustine compared with mitoxantrone and predinsone for advanced hormone refractory prostate cancer. N Eng J Med 2004;351:1513-20.
39. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA;TAX 327 Investigators. Docetaxel plus predinsone or mitoxantrone plus predinose for advanced prostate cancer. N Eng J Med 2004;351:1502-12.
40. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
41. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;16:1886-901.
42. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.